Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerRahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Analysis of evolutionary dynamics and clonal architecture in prostate cancerJake R Conway, Alok K Tewari, Sabrina Y Camp, et al.
Cancer Research Communications|February 5, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction CancersAndrew H Ko, Joseph Chao, Marcus S Noel, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Cancer Immunology Research|January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with CancerHewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
British Journal of Cancer|May 19, 2023
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomasNitya Raj, Jennifer A Chan, Stephanie J Wang, et al.
The Journal of Clinical Investigation|October 22, 2024
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancerRu M Wen, Jessica C Stark, G Edward W Marti, et al.
Clinical Colorectal Cancer|March 13, 2026
Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal CancerAndrea Bocobo, Julia Whitman, Bridget P Keenan, et al.
Nature Cancer|April 28, 2026
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancerChengyi Li, Fang Ke, Hongyi Zhao, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerRahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Analysis of evolutionary dynamics and clonal architecture in prostate cancerJake R Conway, Alok K Tewari, Sabrina Y Camp, et al.
Cancer Research Communications|February 5, 2025
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction CancersAndrew H Ko, Joseph Chao, Marcus S Noel, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Cancer Immunology Research|January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with CancerHewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.
Urologic Oncology|July 26, 2021
A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II studyYaoYao Pollock, Li Zhang, Stacey A Kenfield, et al.
British Journal of Cancer|May 19, 2023
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomasNitya Raj, Jennifer A Chan, Stephanie J Wang, et al.
The Journal of Clinical Investigation|October 22, 2024
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancerRu M Wen, Jessica C Stark, G Edward W Marti, et al.
Clinical Colorectal Cancer|March 13, 2026
Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal CancerAndrea Bocobo, Julia Whitman, Bridget P Keenan, et al.
Nature Cancer|April 28, 2026
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancerChengyi Li, Fang Ke, Hongyi Zhao, et al.
Pageof 20